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Abstract Recently we constructed yeast cells that either
express the human estrogen receptor α or the human
androgen receptor in combination with a consensus ERE or
ARE repeat in the promoter region of a green fluorescent
protein (yEGFP) read-out system. These bioassays were
proven to be highly specific for their cognate agonistic
compounds. In this study the value of these yeast bioassays
was assessed for analysis of compounds with antagonistic
properties. Several pure antagonists, selective estrogen
receptor modulators (SERMs) and plant-derived com-
pounds were tested. The pure antiestrogens ICI 182,780
and RU 58668 were also classified as pure ER antagonists
in the yeast estrogen bioassay and the pure antiandrogen
flutamide was also a pure AR antagonist in the yeast
androgen bioassay. The plant-derived compounds flavone
and guggulsterone displayed both antiestrogenic and anti-
androgenic activities, while 3,3′-diindolylmethane (DIM)
and equol combined an estrogenic mode of action with an
antiandrogenic activity. Indol-3-carbinol (I3C) only showed
an antiandrogenic activity. Coumestrol, genistein, naringe-
nin and 8-prenylnaringenin were estrogenic and acted
additively, while the plant sterols failed to show any effect.
Although hormonally inactive, in vitro and in vivo
metabolism of the aforementioned plant sterols may still
lead to the formation of active metabolites in other test
systems.
Keywords Agonist . Antagonist . Plant hormones .
Synthetic antiestrogens . Yeast estrogen bioassay .
Yeast androgen bioassay
Introduction
For drug design, specific antiestrogens and antiandrogens
are important to treat breast and prostate tumours via
mediation by the human estrogen receptor α (hERα) or the
human androgen receptor (hAR), respectively [1, 2].
Specific agonists for hERα might be used to treat
climacteric complaints in females, while specific agonists
for hAR might be used to treat libido loss, impotence or
muscle weakness in males. Synthetic compounds like
tamoxifen, 4-hydroxytamoxifen, ICI 182,780, ICI 164,384,
raloxifen, RU 58668 and nafoxiden were designed and their
antiestrogenic activity in breast cells was proven to be useful
to treat patients with breast cancer. Tamoxifen and its more
active metabolite 4-hydroxytamoxifen are routinely used for
the treatment of estrogen-dependent breast cancers [3].
However, after 5 years of treatment, most breast carcinoma
become resistant to tamoxifen. Moreover, tamoxifen is a
selective estrogen receptor modulator (SERM) showing
antagonistic effects in breast tissue, agonistic effects on
bone and either agonistic or antagonistic effects on the
endometrium and vaginal epithelium, depending on the
intrinsic 17β-estradiol (E2) serum levels. Prolonged use of
tamoxifen is associated with an increased risk of endome-
trial cancer, but has beneficial effects on the bone and
serum lipid profile [4, 5]. The pure antiestrogens ICI
182,780 and ICI 164,384 are more potent than tamoxifen in
inhibiting the growth of breast cancer cells, but lack the
beneficial effects of tamoxifen. However, they are also
antiestrogenic on the endometrium and are not associated
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with an increased risk of endometrial cancer [6, 7]. ICI
182,780 is often administered by deep intramuscular
injections in cases of tamoxifen resistance [8]. Raloxifen,
on the other hand, acts as an antagonist on the breast,
showed beneficial effects on the bone, but displayed no
estrogenic side effects on the endometrium. Therefore,
raloxifen is a promising alternative for tamoxifen. More-
over, raloxifen is currently being tested for chemopreven-
tion in women whose risk at breast cancer is moderately
increased [9]. RU 58668 is a strong pure antagonist, just
like ICI 182,780 and ICI 164,384. RU 58668 is poorly
water-soluble compound and has a weak oral bioavailabil-
ity, but RU 58668-loaded liposomes are currently being
evaluated to treat multiple myeloma [10]. Nafoxiden is a
derivative of tamoxifen that has an antiproliferative effect
on glioma cells and cultured pulmonary artery endothelial
cells [11, 12]. Moreover, an antiangiogenic effect is
observed for the latter cell type.
The fact that some of these compounds can act both as
estrogens and antiestrogens is rather confusing when
dealing with screening assays for testing these types of
properties. Many researchers assumed first that tamoxifen
and 4-hydroxytamoxifen were classical and pure antiestro-
gens. As a result they decided in favour of transcription
activation assays based on mammalian cell lines, most often
a breast cancer cell, because yeast screens were unable to
show the antagonistic activities of tamoxifen and 4-
hydroxytamoxifen. In this aspect the outcomes using yeast
assays were odd as both compounds behaved as ER
agonists instead of antagonists [13–15]. Later, more
specific observations showed that both compounds are
partial agonists with respect to transcription activation
assays based on different mammalian cell lines, as well as
in cellular proliferation tests based on breast tumour cell
lines [16]. Thus, as tamoxifen and 4-hydroxytamoxifen are
not pure antagonists, but selective estrogen receptor
modulators (SERMs), the observed agonistic activities as
determined in yeast-based estrogen bioassays correlate
relatively well with the growth response of endometrial
cells and of breast cells in an estradiol-free environment
[17]. Since the uterotrophic assay, measuring the uterus
weight gain in the rat, is still the gold standard for testing
estrogenicity, one might just as well say that yeast-based
assays as well as the well-developed in vitro reporter assays
using human breast cancer, Chinese hamster ovary (CHO)
or human U2-OS bone cells are suitable tests to determine
the estrogenic potency of a given compound [18–20].
In the present study we demonstrate that the yeast
estrogen and androgen bioassays are easy-to-handle tools to
identify the possible agonistic and antagonistic properties of
man-made chemicals. In addition, several plant-derived
compounds like coumestrol, campesterol, 3,3′-diindolyl-
methane (DIM), equol, flavone, genistein, guggulsterone,
indol-3-carbinol (I3C), ipri-flavone, naringenin, 8-prenyl-
naringenin, resveratrol and β-sitosterol were tested. The
antagonistic activities were examined with coadministration
of 17β-estradiol (E2) or testosterone (T) that caused a half-
maximal or near maximal response in the yeast estrogen or
androgen bioassay, respectively. The outcome of yeast-
based testing together with results obtained with different
mammalian cell lines will help researchers to elicit the
mechanism of action of agonists, partial agonists and pure
antagonists.
Materials and methods
Chemicals
Chlomiphene citrate, 17β-estradiol, equol, genistein, fla-
vone, flutamide, Z-guggulsterone, indole-3-carbinol,
8-prenylnaringenin, resveratrol, tamoxifen and 4-hydroxy-
tamoxifen were obtained from Sigma. ICI 182,780 was
obtained from Tocris. Campesterol, β-sitosterol and 17β-
testosterone were obtained from Steraloids; dimethyl
sulfoxide (DMSO) from Merck; 3,3′-diindolylmethane
from LKT Lab. Inc.; ipri-flavone from Aldrich; and ICI
164,384, nafoxiden, raloxifen and RU 58668 were a gift of
NV Organon (Oss, The Netherlands). Naringenin was
purchased from Apin Chemical Limited and coumestrol
from Fluka Biochemika. Chemicals to prepare the growth
media and the preparation of the growth media for yeast
cells were as described previously [21].
Yeast estrogen and androgen bioassays with fluorescence
measurement
Cultures of the yeast estrogen and androgen biosensor were
grown overnight at 30 °C with vigorous orbital shaking [21,
22]. At the late log phase, the cultures of both cytosensors
were diluted in the selective MM/L medium to an OD value
at 630 nm between 0.04 and 0.06. For exposure, 200-μL
aliquots of this diluted yeast culture were pipetted into each
well of a 96-well plate and 2 μL of a stock solution of
compound in DMSO was added to test the agonistic
properties of these compounds. To test the antagonistic
properties of the compounds, 1-μL amounts of the
compound stock solutions were coexposed with 1 μL of
E2 or T stock solutions giving about a half-maximal and a
near maximal response (i.e. 80–100% of the maximal
response). DMSO and control samples containing only E2
or T were included in each experiment and each sample
concentration was assayed in triplicate. Exposure was
performed for 24 h at 30 °C and orbital shaking with
125 rpm. Fluorescence and OD were measured at 0 and
24 h directly in a SynergyTM HT Multi-Detection Micro-
1112 Anal Bioanal Chem (2008) 390:1111–1119
plate Reader (BioTek Instruments Inc., USA) using excita-
tion at 485 nm and measuring emission at 530 nm. The
fluorescence signal was corrected with the signals obtained
with the MM/L medium containing DMSO solvent only. In
order to check whether a sample was toxic for the yeast
cells, densities of the yeast culture were determined by
measuring the OD at 630 nm.
Results
The estrogen, antiestrogen, androgen and antiandrogen
activities of several compounds were tested with the in-
house-developed yeast hormonal bioassays [21, 22]. In
order to study the agonist activities, pure compounds were
added. The antiestrogenic and antiandrogenic properties of
the compounds were tested by coadministration of E2 and
T, respectively. Figure 1 shows the responses of the known
pure antiestrogens ICI 182,780 and RU 58668 in the yeast
estrogen bioassay. These pure antiestrogens did not show
any agonistic activity, but with respect to ICI 182,780 an
inhibition of the response caused by E2 was observed at
100 nM. In combination with E2 a partial inhibition of
only 25% was identified and the inhibiting activity of ICI
182,780 was only observed in combination with a dose of
E2 that gave a near maximal response (1.5 nM). The
inhibiting activity of RU 58668 was more pronounced
when tested in combination with a dose of E2 that gives a
near maximal response then when tested in combination
with a dose of E2 that gives about a half-maximal response
(0.6 nM), 70% versus 40%, respectively (data of the latter
not shown). Table 1 gives an overview of all the determined
responses. Remarkably, the pure antiestrogen ICI 164,384
did not show an estrogenic or antiestrogenic activity
(Table 1).
Figure 2a shows the responses of the SERMs tamoxifen,
4-hydroxytamoxifen, raloxifen and chlomiphene citrate in
the yeast estrogen bioassay. Figure 2b shows the responses
of these compounds when tested in combination with a
dose of E2 that gives about a half-maximal response
(0.6 nM). These SERMs all show an estrogenic activity
from 3 μM onwards. When tested in combination with
0.6 nM E2, these compounds turn out to be additive in the
yeast system. Similar results were obtained with the SERM
nafoxiden (Table 1).
In the yeast androgen bioassay, using T as a positive
agonist reference and flutamide as a positive antagonist
reference, all the pure antiestrogens and SERMs turned out
to be completely inactive (Table 1).
Figure 3a shows the responses of the plant-derived
compound I3C and its major digestive product DIM in the
yeast estrogen bioassay. I3C does not show an estrogenic or
antiestrogenic activity, but DIM displays an estrogenic
activity and when tested in combination with E2, DIM
acted additively. Figure 3b shows the responses of I3C and
DIM in the yeast androgen bioassay. Neither compound
shows an androgen agonist activity, but both inhibit the
response caused by T. I3C is thought to be the major active
compound in cruciferous vegetables like broccoli, Brussels
sprouts and cauliflower, and together with its derivative
DIM, exhibit promising cancer-protective properties in
vitro and in vivo [23–25]. DIM was shown to be an ER
agonist and considered as the first example of a plant-
derived pure AR antagonist. DIM suppressed cell prolifer-
ation of androgen-dependent LNCaP cells and inhibited
dihydrotestosterone-stimulated DNA synthesis [24]. Similar
effects of DIM were observed in PC-3 cells, but only when
these cells were cotransfected with a wild-type androgen
receptor expression plasmid [24]. Thus, the activity found
in the yeast estrogen bioassay (Fig. 3a) corresponds with
the known agonistic effect of DIM via the estrogen
receptor. The activities as measured in the yeast androgen
bioassay (Fig. 3b) are in agreement and confirm the
antiandrogenic activities of I3C and DIM on prostate
cancer cells.
The estrogenic activity of equol, the major active
metabolite of the phytoestrogen daidzein, one of the main
isoflavones found abundantly in soy, is well known. The
present study shows that equol is also active as an ER
agonist in the yeast estrogen bioassay (Table 1). Its relative
estrogenic potency (REP) compared with E2 is about
10,000 times lower (data not shown). Recent studies
demonstrate that equol can modulate reproductive function
and is a novel antiandrogen that inhibits prostate growth
[26, 27]. That equol might be a potent in vivo AR
antagonist is reflected by the fact that equol is patented
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Fig. 1 Responses of the pure estrogen receptor antagonists ICI
182,780 and RU 58668 in the yeast estrogen bioassay without 17β-
estradiol (closed symbols) and by coexposure with 1.5 nM 17β-
estradiol (open symbols)
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for treating androgen-mediated diseases [28]. According to
a study by Lund et al., equol does not bind to prostate hAR,
but specifically binds to 5α-dihydrotestosterone (5α-DHT),
but not T, with high affinity, thus preventing 5α-DHT from
binding to the hAR [26]. The present study demonstrates
that equol can inhibit the response caused by T in the yeast
androgen bioassay, thus acting as an AR antagonist. If
excluding the binding to T, this antiandrogenic effect in
yeast is most likely caused by its ability to either bind to or
inactivate the hAR. Overall, the observed activities in the
yeast estrogen and androgen bioassays correlate well with
the known hormonal effects of equol in mammalian
systems.
Furthermore, a number of compounds belonging to one
of the major classes of the phytoestrogens, the flavonoids,
were tested. Flavonoids are widely distributed throughout
the plant kingdom and are of interest owing to their
biological, pharmacological and therapeutic potential [29].
Genistein, the main representative chemical of the flavo-
noids, has been shown to have a relative binding affinity for
hERα of 0.45 (E2=100) and agonist activities in transcrip-
tion activation assays with ERα and ERβ [21, 30–32]. The
estrogenic properties of genistein, naringenin and 8-pre-
nylnaringenin were similar as described before [21]. These
compounds are ER agonists and act additively when tested
in combination with E2 (Table 1). They turned out to be
Table 1 Responses of compounds in the yeast estrogen and yeast androgen bioassay expressing yEGFP in response to estrogens and androgens
respectively
Compound CAS
no.
Yeast estrogen bioassay Yeast androgen bioassay
Agonist 0.6 nM E2
antagonista
1.5 nM E2
antagonista
Comments Agonist 70 nM
17β-T
antagonistb
1 μM
17β-T
antagonistb
Comments
17β-Estradiol 50-28-2 + NA NA Strong
agonist
+ + + Agonist and
antagonist
17β-Testosterone 58-22-0 – – – + NA NA Strong
agonist
ICI 164,384 – – – – – –
ICI 182,780 129453-61-8 – – + Weak
antagonist
– – –
RU 58668 – + + Weak
antagonist
– – –
Flutamide 13311-84-7 – – – – + + Strong
antagonist
Tamoxifen 10540-29-1 + – – Additive – – –
Hydroxytamoxifen 68047-06-3 + – – Additive – – –
Raloxifen 82640-04-8 + – – Additive – – –
Chlomiphene citrate 50-41-9 + – – Additive – – –
Nafoxiden + – – Additive – – –
Indol-3-carbinol 700-06-01 – – – – + + Weak
antagonist
Diindolylmethane + – – Additive – + + Strong
antagonist
Flavone 525-82-6 – + + Strong
antagonist
– + + Strong
antagonist
Ipriflavone 35212-22-7 – – – – – –
Guggulsterone 39025-23-5 – + + Strong
antagonist
– + + Strong
antagonist
β-Sitosterol 000083-46-5 – – – – – –
Campesterol 474-62-4 – – – – – –
Resveratrol 501-36-0 – – – – – –
Genistein 446-72-0 + – – Additive – – –
Equol 94105-90-5 + – – Additive – + + Antagonist
Naringenin 480-41-1 + – – Additive – – –
8-Prenylnaringenin 53846-50-7 + – – Additive – – –
Coumestrol 479-13-0 + – – Additive – – –
NA not applicable, + positive response as an agonist or antagonist, − negative response as an agonist or antagonist
a Antagonism tested in the yeast estrogen bioassay by coadministration of 0.6 or 1.5 nM 17β-estradiol
b Antagonism tested in the yeast androgen bioassay by coadministration of 70 or 1,000 nM testosterone
1114 Anal Bioanal Chem (2008) 390:1111–1119
inactive as AR agonists or antagonists (Table 1). The
flavonoid coumestrol belongs to the coumestrans and
showed the same activity profile as genistein, naringenin
and 8-prenylnaringenin (Table 1).
The flavonoid flavone and the plant sterol guggulsterone
did not show estrogenic activity, but both compounds
inhibited the signal caused by E2 (Fig. 4a). This inhibiting
activity was more pronounced when tested in combination
with a dose of E2, giving a near maximal response.
Figure 4b shows the responses of flavone and guggulster-
one in the yeast androgen bioassay. Neither compound
showed androgenic activity, but both were able to inhibit
the signal caused by T.
Flavone has already been demonstrated to lack binding
affinity for the ER and is known as a weak ER antagonist
[14, 30]. Besides that this antiestrogenic effect was con-
firmed by our results (Fig. 4a), the present work shows that
flavone also acts as an AR antagonist in a yeast androgen
bioassay (Fig. 4b). Guggulsterone is an active substance in
guggulipid, an extract of the guggul tree, Commiphora
mukul. Guggulipid is used to treat a variety of disorders in
man, including dyslipidemia, obesity, arthritis and inflam-
mation. In cell-based functional cotransfection assays,
guggulsterone was shown to be an antagonist on the
androgen, glucocorticoid and mineralocorticoid receptor
(AR, GR and MR), but an agonist on the progesterone and
estrogen receptor (PR and ER) [32]. However, guggulsterone
displayed agonist activity in functional assays with mamma-
lian cell lines expressing endogenous AR, GR, PR and ER
[33]. In the present work, using yeast-based estrogen and
androgen bioassays, we show that guggulsterone not only
acts as an AR antagonist, but also acts as an ER antagonist.
The plant sterols campesterol and β-sitosterol did not
show an effect and also ipri-flavone and resveratrol were
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Fig. 3 Responses of the plant-derived compounds ipri-flavone, indol-
3-carbinol (I3C) and diindolylmethane (DIM) in the yeast estrogen
and androgen bioassays: a shows the responses of these compounds in
the yeast estrogen bioassay without 17β-estradiol (closed symbols)
and by coexposure with 0.6 nM 17β-estradiol (open symbols); b
shows the responses of these compounds in the yeast androgen
bioassay without testosterone (closed symbols) and by coexposure
with 70 and 1,000 nM testosterone (open symbols)
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Fig. 2 Testing the agonistic and antagonistic properties of selective
estrogen receptor modulators (SERMs) in the yeast estrogen bioassay:
a shows the responses of tamoxifen (TAM), 4-hydroxytamoxifen
(4OH-TAM), raloxifene (RAL) and chlomiphene citrate (CC); b
shows the responses of these compounds when tested in combination
with 0.6 nM 17β-estradiol
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unable to show a response. Although it is considered to be
proven that β-sitosterol is an endocrine disruptor in fish, its
mechanism of action is mainly unknown [34]. Resveratrol
is a natural product found in red wine and is thought to
have cancer preventive properties owing to its AhR
antagonistic activity [35]. Resveratrol is classified as a
phytoestrogen, but hormonal activities of this compound
are not reported and neither were they found in this study.
In the present work relatively few compounds were
tested that were able to show an effect in the yeast androgen
bioassay. Previously, however, a large number of andro-
genic compounds were tested and used to perform a
quantitative structure–activity relationship (QSAR) ap-
proach [36]. That yeast-based assays are extremely useful
for QSAR model approaches is further demonstrated by
Fig. 5, which shows the response of E2 in the yeast
androgen bioassay and its effect in combination with a dose
of T that gives a half-maximal and a near maximal
response. Together with the data from Table 1, these
dose–response curves demonstrate that E2 combines three
activities: it is an ER agonist, a weak AR agonist and an
AR antagonist. The dip in the 17β-estradiol curve in
combination with the dose of T that gives a half-maximal
response is expected, reflecting that at this concentration E2
starts to act as an AR antagonist, while at slightly higher
concentrations it starts to act as an AR agonist too.
Discussion
The antiestrogens and SERMs tested in this study on
estrogenic, antiestrogenic, androgenic and antiandrogenic
activities in yeast-based bioassays show an activity profile
that corresponds with the activities and effects that these
compounds have on the uterus in animals and endometrial
cells in vitro. Only the pure antiestrogen ICI 164,384 did
not show its antiestrogenic activity in the yeast estrogen
bioassay. Various explanations can be envisaged for this
discrepancy, such as the absence of cell-specific factors
(coactivators and corepressors), the presence of endogenous
estrogen binding proteins, and the selective uptake of
estrogenic compounds in yeast cells [37]. Although the
long apolar 7α side chain in combination with its very polar
tail ending might prevent ICI 164,384 uptake by diffusion
or accelerate active excretion, the last two explanations
seem unlikely as all compounds tested so far in our yeast-
based bioassays, ranging from polar compounds like estriol
and equol to the more apolar compounds like diethylstil-
bestrol (DES) and BDE-39, were able to show their specific
activity and all within 6 h after exposure [21, 22, 36].
Moreover, the predominant mechanism of antiestrogen
action of ICI 164,384 in both uterus and breast involves
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Fig. 5 Response of 17β-estradiol in the yeast androgen bioassay
(standard deviations/error bars are not visible because they are smaller
than the size of the symbols)
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Fig. 4 Responses of flavone and guggulsterone in the yeast estrogen
and androgen bioassays: a shows the responses of these compounds in
the yeast estrogen bioassay without 17β-estradiol (closed symbols)
and by coexposure with 0.6 and 1.5 nM 17β-estradiol (open symbols);
b shows the responses of these compounds in the yeast androgen
bioassay without testosterone (closed symbols) and by coexposure
with 70 and 1,000 nM testosterone (open symbols)
1116 Anal Bioanal Chem (2008) 390:1111–1119
the rapid loss and turnover of estrogen receptor content
[7, 38]. The absence of cell-specific factors is thus probably
also not a valid explanation for the inactivity of ICI
164,384 in yeast. A possible explanation could be that
rapid formation of active hERα (the hERα is continuously
expressed in our yeast estrogen bioassay by use of the
strong and constitutive GPD promoter) exceeds the ICI
164,384-induced inactivation of hERα. This might also
explain the relative insensitivity of the yeast estrogen
bioassay to detect the antiestrogenic activity of ICI
182,780. The mechanism of action of this compound
partially overlaps that of ICI 164,384, but the overall
antiestrogenic potency is much stronger. The antiuterotro-
phic potency of ICI 182,780 is more than tenfold greater
than that of ICI 164,384 and ICI 182,780 binds five times
stronger to ERα than ICI 164,384 [39–41], possibly
explaining why the antiestrogenic effect of ICI 182,780 is
just visible in yeast.
However, the mechanisms of antiestrogenic action of
ICI 164,384 and ICI 182,780 are rather complex and not
fully understood and the possible explanations for the
relative insensitivity of yeast to detect their antiestrogenic
activity as described above, including the selective uptake
of estrogenic compounds, cannot be excluded by the
current data. In addition, it is also possible that ICI
164,384 is unable to inactivate hERα in yeast at all or that
ICI 164,384 and ICI 182,780 are both poorly soluble
compounds in yeast growth media, but dissolve in cell
culture media due to the presence of 5–15% serum. The
different in vitro and in vivo mechanisms involved in the
antiestrogenic effects of pure antiestrogens and SERMs are
reviewed by Jordan [1] and it is illustrated that there is no
unifying theory that can explain the target site-specific
actions of SERMs. There are many inconsistent data and
until recently the complexity of (anti)hormone action was
not anticipated [1].
The determined activities of the plant-derived com-
pounds, e.g. I3C, DIM, equol, flavone and guggulsterone,
correlate well with their known properties. Here we show
for the first time that flavone is not only an ER antagonist,
but also acts as an AR antagonist in a yeast androgen
bioassay and that guggulsterone is not only an AR
antagonist, but also acts as an ER antagonist in a yeast
estrogen bioassay. When tested in the yeast androgen
bioassay, there is about a 100-fold difference between the
inhibiting concentrations needed to inhibit the half-maximal
and near maximal response. This is due to the fact that there
is a 14 times difference in the T concentration, 70 and
1,000 nM, respectively. In the yeast estrogen assay there is
only a 2.5 difference in the E2 concentration needed for a
half-maximal and near maximal response, 0.6 and 1.5 nM,
respectively. The observed differences in the yeast andro-
gen bioassay are thus due to common receptor kinetics.
Results show that the agonistic and additive effects of
compounds can be observed best in combination with a
dose of E2 or T that gives a half-maximal response. It is
advisable to study the antagonistic effects both with a dose
of an agonist that gives a half-maximal response and a dose
that gives a near maximal response.
Yeast estrogen and androgen bioassays are relatively
insensitive compared with their mammalian counterparts
and the relatively high EC50 values of the receptor agonists
might, from a physiological point of view, be less relevant.
However, in a physiological context, 1 nM E2 or the
circulating level in premenopausal women, 272 pg mL−1,
will maximally activate an ERα estrogen response element
(ERE) in vivo [1]. The maximal response in yeast estrogen
bioassays is obtained at E2 concentrations between 1 and
2 nM. Thus one might just as well argue that yeast-based
assays are at least as relevant as their mammalian counter-
parts, showing a maximal response in the low picomolar
range. The relatively low EC50 values for agonists obtained
with human cell lines most likely reflect the hormone
dependence of the tumour cell lines for growth and their
sensitivity for antihormone treatment. In addition, in general
the relative estrogenic and androgenic potencies (REPs and
RAPs) determined in the yeast estrogen and androgen
bioassay, respectively, show a good correlation with those
determined in vitro with mammalian cell-based assays and
the in vivo Allen and Doisy test for estrogenic activity and
the in vivo Herschberger test for androgenic activity [20–22].
Thus, yeast cells are less sensitive, but the determined
effects and relative potencies are very specific. The same is
valid for the antagonistic responses of the compounds
described in this study. Only the differences in the relative
potencies of tamoxifen and both ICI compounds between
yeast and mammalian cell systems are relatively high.
Differences between data obtained with endometrial,
prostate, breast and yeast cells may be explained by
different mechanisms that underlie endocrine response
(e.g. as in the case of ICI 164,384), different organ and
species sensitivities (e.g. assembling and presence of both
coactivators and corepressors, amount of receptors), limi-
tations of the assay techniques (e.g. selective uptake,
solubility), differences in metabolism and many more.
These differences not only occur between yeast and
mammalian cells, but also between different mammalian
cell types [1].
The effects observed with tamoxifen have been inten-
sively investigated and it was shown that different breast
cell lines show different responses, agonistic or antagonis-
tic, with tamoxifen and other compounds [42–44]. More-
over, breast cells often not only express hERα, but also
hERβ [1, 42]. This coexpression of hERβ has a great
influence on how the cells respond to estrogens and other
hormones. In general the hERβ decreases the response of
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the hERα and acts as a kind of a regulator (repressor) of
hERα [21, 45]. Of course this may have physiological
importance, but it complicates the interpretation of the
results.
The importance of the metabolism and the differences in
the metabolism of compounds has been underestimated for
a long time. Differences in metabolism were often
responsible for the differences found between different cell
lines and between cell lines and yeast-based bioassays [36,
46, 47]. Estrone for instance showed a REP of 0.2 in a
proliferation test based on human breast cancer cells (E-
screen) and the yeast estrogen bioassay, but was equally
potent to E2 in a transcription activation assay based on
human T47-D breast cancer cells [16, 21, 46]. In the ER-
CALUX test with the T47-D breast cancer cells, the 17β-
hydroxysteroid dehydrogenase 3 enzyme was responsible
for the conversion of estrone into E2 and vice versa [46].
Another example is benzo[a]pyrene (B[a]P). This com-
pound was shown to be estrogenic in different mammalian
cell reporter gene (MCRG) systems and in this aspect the
outcomes using yeast assays were odd as B[a]P is
completely inactive in yeast estrogen screens [14]. Howev-
er, more specific observations showed that the hydroxylated
benzo[a]pyrene metabolites are responsible for the estrogen
receptor-mediated gene expression induced by benzo[a]
pyrene in the in vitro mammalian systems, but do not elicit
uterotrophic effects in vivo [47]. Yeast generally lacks the
metabolic capacity of mammalian cells. Agonists or
antagonists that require metabolic activation for conversion
to a bioactive state may not be detected in yeast. In contrast,
compounds that are metabolically inactivated by mam-
malian cells may persist and be especially potent in yeast
assays.
Conclusion
Yeast cells might by definition not necessarily be relevant
for the higher vertebrates, but nevertheless the relative
simplicity of yeast versus mammalian cells can be very
helpful in studying the mechanism of action of different
cellular processes. Overall, it can be concluded that in order
to investigate the hormonal properties of different com-
pounds and their mechanism of action, there is no superior
assay system. The only way to elicit the mechanism of
action of compounds is to be aware of the limitations of the
different assay techniques, to fully understand the mecha-
nism in the assay itself (including the metabolism and
possible cross talk from other nuclear receptors) and to
compare the outcomes from the different assay types.
Different assay types are thus complementary and are
needed together to be able to elicit the mechanism of
actions of compounds and their metabolites [48].
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